Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients

Maristella Pitzalis†*, Maria Laura Idda†*, Valeria Lodde2, Annalisa Loizedda1, Monia Lobina1, Magdalena Zoledziewska1, Francesca Virdis1, Giuseppe Delogu2, Federica Pirinu2, Maria Giuseppina Marinì1, Maura Mingoia1, Jessica Frau1, Lorena Lorecice1, Maria Fronza1, Daniele Carmagini1, Elisa Carta1, Valeria Orru1, Sergio Uzzau2, Paolo Sollà2, Federica Loi5, Marcella Devoto1, Maristella Sterri1, Edoardo Fiorillo1, Matteo Floris2, Ignazio Roberto Zarbo6, Eleonora Cocco3,4, Francesco Cucca2†.

†Equally contributed first authors
^Equally contributed last authors

* Correspondence:
Maria Laura Idda, Maristella Pitzalis
marialaura.idda@irgb.cnr.it, maristella.pitzalis@irgb.cnr.it

1. Institute for Genetic and Biomedical Research, National Research Council, Monserrato, Cagliari
2. Department of Biomedical Sciences, University of Sassari, Sassari
3. Regional Multiple Sclerosis Center, ASSL Cagliari, ATS Sardegna, Cagliari
4. Department of Medical Science and Public Health, University of Cagliari, Cagliari
5. Department of Biomedical Sciences, University of Sassari - Unit of Clinical Microbiology, AOU Sassari, Sassari
6. Department of Medical, Surgical and Experimental Sciences, University of Sassari - Neurology Unit, AOU Sassari, Sassari
7. Osservatorio Epidemiologico Veterinario Regionale, Istituto Zooprofilattico Sperimentale della Sardegna, Cagliari
8. Dipartimento di Medicina Traslazionale e di Precisione, Università la Sapienza, Rome, Italy

Keywords: SARS-CoV-2; multiple sclerosis; humoral immunity; disease-modifying therapy; vaccine efficacy; BNT162b2; COVID-19.

Abstract

Objectives: Vaccination against COVID-19 is highly recommended to patients affected by multiple sclerosis (MS); however, the impact of MS disease-modifying therapies (DMTs) on the immune response following vaccination has been only partially investigated. Here, we aimed to elucidate the effect of DMTs on the humoral immune response to mRNA-based anti-SARS-CoV-2 vaccines in MS patients.

Methods: We obtained sera from 912 Sardinian MS patients and 63 healthy controls 30 days after the second dose of BNT162b2 vaccine and tested them for SARS-CoV-2 response using anti-Spike (S) protein-based serology. Previous SARS-CoV-2 infection was assessed by anti-Nucleocapsid (N) serology. Patients were either untreated or undergoing treatment with a total of 13 different DMTs. Differences between treatment groups comprised of at least 10 patients were assessed by generalized linear mixed-effects model. Demographic and clinical data and smoking status were analyzed as additional factors potentially influencing humoral immunity from COVID-19 vaccine.

Results: MS patients treated with natalizumab, teriflunomide, azathioprine, fingolimod, ocrelizumab, and rituximab showed significantly lower humoral responses compared to untreated patients. We did not observe a statistically significant difference in response between patients treated with the other drugs (dimethyl fumarate, interferon, alemtuzumab and glatiramer acetate) and untreated patients. In addition, older age, male, sex and active smoking were significantly associated with lower antibody titers against SARS-CoV-2. MS patients previously infected with SARS-CoV-2 had significantly higher humoral responses to vaccine than uninfected patients.
Conclusion: Humoral response to BNT162b2 is significantly influenced by the specific DMTs followed by patients, as well as by other factors such as previous SARS-CoV-2 infection, age, sex, and smoking status. These results are important to inform targeted strategies to prevent clinically relevant COVID-19 in MS patients.
Introduction
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) that has spread rapidly worldwide since its first appearance in China in December 2019 (1).

The virus is characterized by high infectivity, which is also sustained by transmission from presymptomatic/asymptomatic carriers, resulting in an average number of secondary infections by an infected individual; indeed, the R0, indicating the average number of people who will contract COVID-19 from one infected person, was 2.79 for the original strain and of 5.08 for the emerging delta variant. These unfortunate features of SARS-CoV-2 have resulted in large numbers of infected individuals (more than 230 million molecularly identified individuals) and deaths (more than 4.7 million) through September 21 [https://www.worldometers.info/coronavirus/].

Elimination of the virus and clinical recovery from COVID-19 mainly relies on the immune response mounted and orchestrated by specific B and T cell subpopulations and mediated by the production of neutralizing antibodies (2,3). The most relevant protective antibodies target the SARS-CoV-2 trimeric glycoprotein Spike (S) (4), which mediates the viral entry by interacting with the surface protein angiotensin-converting enzyme 2 expressed in a large set of human cells (5).

Although unprecedented medical and scientific efforts have been made since the pandemic outbreak to limit its clinical impact, to date there are no clearly effective antiviral therapies that can be readily and widely administered to infected people. Instead, vaccination has clearly emerged as the most effective strategy to counter the spread of SARS-CoV-2 infection and minimize its clinical impact (6). As of 19 September 2021, there were 22 vaccines approved in different countries and 37 in phase III clinical trials [https://covid19.trackvaccines.org]. The mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) directed against the spike glycoprotein of SARS-CoV-2 have proven to be very safe and especially effective in protecting against infection and severe forms of COVID-19 (7). However, the extent of immune response following vaccination and its efficacy in specific categories of individuals, such as those who are immunocompromised or on immunosuppressive therapies, are only partially clarified.

Recently, a few reports have provided the first preliminary data on humoral responses after Pfizer-BNT162b2-COVID-19 vaccination in MS patients, with a special emphasis on those receiving disease modifying therapies (DMTs) (8,9). They suggested that MS patients treated with certain DMTs failed to mount a good protective level of SARS-CoV-2 spike-specific IgG compared to untreated patients. However, the conclusions of these analyses were limited by the small sample sizes and the fact that they did not consider the role of some DMTs and the influence of other elements such as SARS-CoV-2 previous infection or lifestyle on the observed immunologic responses.

Here, we analyzed the humoral response after vaccination with BNT162b2 in a sample of 912 Sardinian MS patients from the Mediterranean island of Sardinia (Italy), which represents the notable exception to the north-south gradient in the frequency of MS in Europe and has one of the highest disease prevalence rates in the world (10). Our findings elucidate the effect of a large spectrum of DMTs and other relevant factors on the humoral responses to BNT162b2, suggesting some categories of MS patients remain at higher risk for SARS-CoV-2 infection following vaccination, and thus informing tailored strategies to prevent COVID-19.
Methods

Study participants
A total of 912 MS patients from the MS clinical centers in Cagliari and Sassari in Sardinia (Italy) were enrolled between April and June 2021. MS patients were diagnosed according to the McDonald criteria. In parallel, 63 individuals from the SardiNIA longitudinal project (11) were recruited as a healthy control group. All patients and controls received two intramuscular injections, 21 days apart, delivered in the deltoid muscle. Each injection contained 30μg of BNT162b2 (0.3ml volume per dose).

Patient information on age, sex, smoking status, disability score, disease subcategory and disease-modifying treatment (DMT) at the time of vaccination was also collected. The full list of MS patient and healthy controls that received COVID-19 vaccination with clinical and demographic characteristics is available in Supplemental Table S1.

Detection of SARS-CoV-2 IgG antibodies
Blood samples from the entire study population of 975 individuals were collected approximately 30 days after injection of the second vaccine dose, in vacutainer tubes containing clot activator with gel separator.

Similarly, blood samples were collected for retrospective analyses on the day of the first vaccine injection from a subset of 612 MS patients and from the 63 control subjects.

To avoid time-dependent artifacts, samples were processed within two hours after blood collection, and serum was stored at -80°C until use.

Detection of anti-SARS-CoV-2-S and anti-SARS-CoV-2-N antibodies in serum samples was performed using the electrochemiluminescence immunoassays Elecsys® Anti-SARS-CoV-S and Elecsys® Anti-SARS-CoV-N (Roche) on the automated Cobas e-411 analyzer, according to the manufacturer's instructions. Anti-S results are expressed as units per ml (U/ml).

Ethics and data collection
The study was approved by the local Ethical Review Boards prot. N° 177/20021/EX2492/CE. All enrolled individuals provided written informed consent. Patient data and samples were coded anonymously to ensure confidentiality during sample processing and data analysis.

Statistical analysis
Normality of baseline distribution of Anti-S antibodies quantified as described above was preliminary assessed with the Shapiro Wilk test. Categorical variables are presented as number and percentage, quantitative variables are presented as median and interquartile range (IQR).

Considering the nature of the outcome (Anti-S, non-negative count data), differences between groups of patients defined by therapy and negative to Anti-N antibody, were assessed by a negative binomial generalized linear mixed-effects model; the contribution of age, sex, Expanded Disability Status Scale (EDSS), disease duration, previous SARS-CoV-2 infection, and the clinical sampling center were also analyzed. A multivariate model was fitted by including each independent variable with a significant effect in univariate analysis (P < 0.20, nominal p accounting for the number of covariates tested). Only treatments available for at least 10 patients were included in the model. Results are presented as IRR (Incidence Rate Ratio) (12), calculated as the exponential of the regression coefficient. Differences between medians were tested by Mann-Whitney test. All statistical analyses were performed using the R software v.4.1.0. P-values <0.05 were considered as statistically significant.
Results

**MS cohort**

The MS cohort analyzed in this study included 658 (73.1%) females and 254 (26.9%) males (female-to-male ratio 2.7:1). Regarding the disease forms, 82.7% of patients were relapsing-remitting MS (RRMS), 1.8% primary progressive (PPMS) and 15.5% secondary-progressive (SPMS), (Table 1). Of the MS patients, 205 (22.5 %) were untreated and 707 (77.5%) treated with various DMTs as follows. The most diffuse common treatments were dimethyl fumarate and interferons (respectively, 22.2% and 19 % of the treated patients) while few patients were treated with methotrexate (0.28%) and cladribine (0.84%). In detail, the MS cohort treated with DMTs was composed as follows: 161 patients assumed dimethyl fumarate, 135 interferons, 96 glatiramer acetate, 75 fingolimod, 75 natalizumab, 56 teriflunomide, 42 ocrelizumab, 17 alemtuzumab, 13 rituximab, 6 cladribine and 2 methotrexate. Only a patient was included in a trial with a Bruton’s tyrosine kinase (BTK) inhibitor. Clinical and demographic characteristic of MS patients that received COVID-19 vaccination -- stratified for DMTs -- are summarized in Table 2.

The impact of disease-modifying therapies on humoral responses to BNT162b2 vaccine

We did not find any significant difference between untreated MS patients and healthy control in anti-S antibodies responses (p = 0.51) suggesting not significative effect of MS disease in the response to BNT162b2 vaccine (Figure 1A).

We applied a negative binomial generalized linear mixed-effects model in patients negative for Anti-N antibodies production, considering only treatments available for at least 10 patients. We did not find significant difference in Anti-S antibodies production between patients treated with dimethyl fumarate (p = 0.22), interferons (p = 0.06), alemtuzumab (p = 0.22) or glatiramer acetate (0.38) and untreated MS patients (here considered as the reference group); all of them were characterized by high levels of antibodies post-COVID-19 vaccination (Table 3).

In contrast, as previously suggested (8,9), a significantly lower level of Anti-S antibodies production in response to vaccination was observed in MS patients treated with teriflunomide (IRR= 0.51, p = 1.44E-05), azathioprine (IRR = 0.37, p = 3.26E-06), natalizumab (IRR = 0.72, p = 0.034), fingolimod (IRR = 0.13, p = 1.89E-39), ocrelizumab (IRR = 0.10, p = 4.88E-38) and rituximab (IRR = 0.22, p = 8.36E-07), compared to untreated patients (Table 3). Of notice is the case of patients treated with natalizumab. Indeed, while the antibodies medians shown in Figure 1A seem to indicate a higher response in patients undergoing this treatment compared to untreated patients, results after adjustment for the significant confounding effects of age, sex and EDSS show an opposite (reduced) anti-S antibodies response. This apparent discrepancy can be explained by the fact that patients treated with natalizumab are overrepresented by female and the youngest among our MS patients, as shown in Table 2.

The impact of prior SARS-CoV-2 infection on humoral responses to BNT162b2 vaccine

The Nucleocapsid Protein (N) antigens of SARS-CoV-2 are found in the viral core but are not present in the corresponding nucleoside-modified mRNA sequence of BNT162b2 vaccine; thus, immunoglobulins targeting N antigens are detectable in the serum of vaccinated individuals only if they have been recently infected with SARS-CoV-2. To check the effect of previous or concurrent COVID-19 infection on humoral immune response to SARS-CoV-2 vaccination, we quantified anti-SARS-CoV-2 antibodies directed against the N protein in serum samples collected at around 30 days after the injection of the second dose. Only one HC was found to be positive for anti-N antibodies (data not shown). Among the 912 MS patients analyzed we found 38 positives for the N protein, suggesting a previous infection. Of these, 25 had previous record of positive RT-PCR tests on respiratory samples and 22 were found positive to anti-N antibodies at the time of their first vaccine dose.

In the 38 MS patients with evidence of a natural exposure to SARS-CoV-2, postvaccination anti-S antibodies levels were significantly higher than patients which didn’t experience SARS-CoV-2 infection (medians 14,000 vs. 1,040 U/ml, Mann-Whitney test p = 2.27E-18). The enhanced immune response to vaccine due to natural infection was also observed in patients treated with fingolimod, albeit to a lesser extent than in patients treated with other DMTs (Figure 1B). Further data are needed to
assess the impact of prior or concurrent infection with SARS-CoV-2 on the immune response to the vaccine in patients treated with DMTs in MS patients.

The impact of sex, age, EDDS and smoking on humoral responses to BNT162b2 vaccine
Analyzing additional factors that may affect interindividual variability in SARS-CoV-2 vaccine responses is extremely important to monitor anti-SARS-CoV-2 vaccine efficacy, particularly in patients affected by MS undergoing DMTs. Our statistical model revealed additional significant effects for age, sex and EDDS, with reduced postvaccination levels of anti-SARS-CoV-2 antibodies directed against the S protein in older (IRR = 0.98, p = 3.85E-03), male individuals (IRR = 0.83, p = 0.021) (Figure 2A-B, and reduced EDDS (IRR=0.93, p = 1.31E-04).

In a recent report, antibodies titers were shown to be lower after COVID-19 vaccination in a healthy cohort of smokers compared to non-smokers (13). We therefore examined the effects of cigarette smoking on humoral response to SARS-CoV-2 vaccine in a subset of 535 MS patients negative for Anti-N antibodies production for whom smoking status was available. Among them, 147 (28.6%) were reported to be active smokers. Our analyses showed that also among MS patients, there was a reduced anti-S antibodies production in smokers (median = 719 U/ml) compared to nonsmokers (median = 1054 U/ml) in response to BNT162b2 vaccine (Mann-Whitney test p = 2.0E-04; Figure 2C).
Discussion

In this study we evaluated the early humoral responses to BNT162b2 vaccine in 912 MS patients and 63 healthy individuals from the SardiNIA longitudinal project (11), an autoimmune prone population (10). The study design allowed us to examine the influence of several DMTs on the levels of total anti-S antibodies in MS patients. We also considered the influence of other relevant variables, such as a past SARS-CoV-2 infection, as well as age, sex, and smoking.

Effect of drugs used in the therapy of MS on the early humoral response to SARS-CoV-2 vaccine

Thirty days after the second dose of vaccine, anti-S antibodies titers elicited by two doses of BNT162b2 were assessed in MS patients undergoing different DMTs compared to untreated MS patients. Specifically, as already reported in previous smaller studies (8,9), patients treated with fingolimod, ocrelizumab, and rituximab have much lower humoral responses than untreated patients (Figure 1A and Table 3). Indeed, anti-CD20 therapies (ocrelizumab and rituximab) and the SP1 modulator fingolimod act directly on B cells, by depleting their availability in circulation or by driving lymphocyte sequestration in the lymph nodes (14,15). To a lesser but still significant extent, early humoral response was also reduced in patients treated with teriflunomide, natalizumab and azathioprine compared with untreated patients. Teriflunomide is an immunomodulator which causes inhibition of rapidly dividing cells, including activated T and B cells (16). Natalizumab, another immunomodulator, prevents lymphocyte migration to the central nervous system (17). Finally, azathioprine, an immunosuppressive drug used in several autoimmune diseases and in kidney transplants, act through bone-marrow suppression (18).

Patients treated with, interferons, glatiramer acetate, and alemtuzumab, show a higher humoral response than untreated patients, which however does not reach statistical significance in our dataset.

Overall, the effects of many of these DMTs on humoral responses to SARS-CoV-2 are consistent with previous analyses reporting their effects on other vaccines. For instance, preserved immune responses after vaccination against other pathogens (e.g. seasonal influenza, tetanus-diphtheria toxins) have been reported in people treated with beta-interferons and dimethyl fumarate (19); likewise, a reduced responses to vaccinations against other pathogens after treatment with fingolimod and B cell depleting anti-CD20 therapies have been reported (19). Furthermore, our findings on responses after BNT162b2 vaccination in patients treated with alemtuzumab and interferons are in agreement with observations indicating that immune responses to vaccinations are well preserved against a number of vaccines, including the tetanus, Hemophilus influenzae type b and meningococcal group C vaccines (19).

Previous SARS-CoV2 infections enhance the early humoral responses to SARS-CoV-2 vaccine

One of the most interesting observations of this study is that patients with natural infection, before or soon after the first vaccine injection had significantly higher humoral responses to vaccine than uninfected patients. Because vaccination aims to stimulate immune responses that mirror natural infection, the finding of enhancement of humoral responses to vaccine in MS patients who have acquired infection, often unnoticed, suggests that for certain DMTs such as fingolimod, an additional boost with a third dose of mRNA vaccine is likely to be effective, as already shown for solid-organ transplant recipients (20) and in the general population (21).

Older age, male sex, and smoking negatively affect vaccine response

In agreement with previous studies (13), we show that in addition to DMTs and prior SARS-CoV-2 infection, both age and sex also influence antibody response to vaccine. Indeed, SARS-CoV-2 antibodies levels against S protein after COVID-19 mRNA vaccine were significantly lower in males and in older patients. These results agree with a very significant reduction in absolute counts of B cells subclasses, including primarily antibody-producing plasma cells, during immunoosenescence and with a more pronounced decrease in males than in females (unpublished results from 4,000 individuals of the SardiNIA study ranging from 18 to 105yrs).

Recently, smoking has been shown to be an important risk factor for the development of complications following SARS-CoV-2 infection (22). Hence, we further evaluated the relationship between antibodies
titers in response to COVID-19 mRNA vaccine and smoking status in a subgroup of 535 patients; our data indicated a significant reduction in antibodies titers in MS patients who were active smokers. This result is in line with the observation of rapid decrease in antibody titers in smokers after influenza vaccination (23) and more generally with the association of smoking with immune system dysfunction (24).

**Concluding remarks and open questions**

The present results highlight the need for an optimal treatment regimen and time schedule for certain DMTs before vaccination to allow repopulation of immune cells and soluble molecules necessary for an appropriate response to the SARS-CoV-2 vaccine, and for resumption of MS therapy after vaccination to prevent a rebound of the autoimmune process underlying the disease. Nevertheless, administration of a third vaccine dose to safely mimic the enhanced humoral responses observed here in SARS-CoV-2 infected MS patients on immunosuppressive therapies may be the first-line strategy to achieve both effective protection against SARS-CoV2 infection and control of MS by DMT.

Still, some open questions remain unsolved. A critical issue is defining a cut-off value for anti-S antibody levels which correlate with protection against SARS-CoV-2 infection and/or severe COVID-19 disease. In one study, a cut-off value of 133 binding antibody (BA) U/ml for the Elecsy anti-S assay was found to predict the presence of neutralizing antibodies (NAb) after natural infection (25). Assuming that, the same cut-off also applies to sera after vaccination, we can predict the presence of NAb after vaccination in most patients undergoing all DMTs except fingolimod and anti-CD20 therapies. Given the large reduction in total antibodies levels in patients undergoing these latter regimens, it is likely that protection associated with Fc-mediated effector functions of non-NAbs, such as antibody-mediated natural killer cell degranulation and neutrophil phagocytosis, is also severely compromised in the same patients (26). Still, all these predictions need to be confirmed by direct testing.

Another relevant question not addressed in this study is if and which lymphocyte subpopulations are contributing to the immune responses to the vaccine under different DMTs and if a cellular immune reaction triggered by the vaccine provides some protection against infection and disease even in patients with inadequate humoral immune responses. Thus, a comprehensive flow cytometry analysis of B and T cells subtypes directed against the Spike protein of SARS-CoV-2 using cells collected from MS patients will be fundamental to also assess the cellular component of the immune responses after vaccination.

Nevertheless, we can conclude that our findings showing differential humoral responses to BNT162b2 vaccine in MS patients on various DMTs have important implications for determining appropriate strategies to ensure an adequate post-vaccination COVID-19 protection while avoiding the risk of a flare-up of inflammatory disease activity.

**Study Funding**
The study was supported by the Italian Foundation for Multiple Sclerosis - FISM (Grant N. 22021/Special/002).

**Glossary:** Multiple sclerosis (MS), disease-modifying therapies (DMTs), severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19), Antibody (Ab), Spike (S), Nucleocapsid (N).

**Acknowledgment**
We thank all the patients and volunteers who generously participated in this study. We would also like to thank all the medical doctors, nurses, and students who have collaborated to the realization of this study.
Reference


### Table 1. Clinical and demographic characteristics of MS patients and healthy controls that received COVID-19 vaccination

<table>
<thead>
<tr>
<th></th>
<th>MS patients</th>
<th>Healthy subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>N.</td>
<td>912</td>
<td>63</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>658 (73.1)</td>
<td>50 (81.0)</td>
</tr>
<tr>
<td>Age in yrs, median (IQR)</td>
<td>48.8 (38.8-57.8)</td>
<td>52.1 (42.2-56.1)</td>
</tr>
<tr>
<td>Disease duration in yrs, median (IQR)</td>
<td>13.6 (7.6 - 21.6)</td>
<td>_</td>
</tr>
<tr>
<td>EDSS, median (IQR)</td>
<td>22 (1 - 4.5)</td>
<td>_</td>
</tr>
<tr>
<td>RRMS, n (%)</td>
<td>752 (82.6)</td>
<td>_</td>
</tr>
<tr>
<td>PPMS, n (%)</td>
<td>16 (1.8)</td>
<td>_</td>
</tr>
<tr>
<td>SPMS, n (%)</td>
<td>142 (15.6)</td>
<td>_</td>
</tr>
<tr>
<td>Smokers, n (%)a</td>
<td>153 (28.6)</td>
<td>_</td>
</tr>
</tbody>
</table>

Abbreviation: RRMS = relapsing-remitting multiple sclerosis; EDSS = Expanded Disability Status Scale; IQR = interquartile range

*aSmoking data were available for a subset of 535 MS patients

### Table 2. Clinical and demographic characteristic of MS patients that received COVID-19 vaccination stratified by DMTs.

<table>
<thead>
<tr>
<th>Therapy</th>
<th>N.</th>
<th>Age in yrs. median (IQR)</th>
<th>% F</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALEM</td>
<td>17</td>
<td>41.3 (36.5-45)</td>
<td>68.8</td>
</tr>
<tr>
<td>AZA</td>
<td>28</td>
<td>58.9 (55.2-64.1)</td>
<td>74.1</td>
</tr>
<tr>
<td>CLA</td>
<td>6</td>
<td>46.8 (37.8-48)</td>
<td>83.3</td>
</tr>
<tr>
<td>DMF</td>
<td>161</td>
<td>44.6 (36.3-51.8)</td>
<td>76.5</td>
</tr>
<tr>
<td>FTY</td>
<td>75</td>
<td>45 (37.8-52.1)</td>
<td>74.6</td>
</tr>
<tr>
<td>GA</td>
<td>96</td>
<td>53.6 (42.8-59.4)</td>
<td>73.0</td>
</tr>
<tr>
<td>IFN</td>
<td>135</td>
<td>47.9 (36.7-54.4)</td>
<td>77.7</td>
</tr>
<tr>
<td>NAT</td>
<td>75</td>
<td>36.3 (31.2-46.2)</td>
<td>76.4</td>
</tr>
<tr>
<td>OCR</td>
<td>42</td>
<td>43.4 (35.4-52.4)</td>
<td>54.8</td>
</tr>
<tr>
<td>RTX</td>
<td>13</td>
<td>53.9 (41.5-56.8)</td>
<td>66.7</td>
</tr>
<tr>
<td>TER</td>
<td>56</td>
<td>51.5 (45.6-56.5)</td>
<td>70.9</td>
</tr>
<tr>
<td>UNT</td>
<td>205</td>
<td>59 (48.3-65.6)</td>
<td>68.9</td>
</tr>
</tbody>
</table>

Abbreviation: F=female; DMT=disease modifying therapy; UNT=untreated; ALEM=alemtuzumab; IFN=interferon; GA=glatiramer acetate; DMF=dimethyl fumarate; NAT=natalizumab; CLA=cladribine; TER=teriflunomide; AZA=azathioprine; FTY=fingolimod; RTX=rituximab; OCR=ocrelizumab; IQR=interquartile range; F=female. Patients treated with methotrexate or included in a trial with Bruton Tyrosine Kinase are not shown in the table.
**Table 3.** Negative binomial generalized linear mixed-effects model of anti-S-Ab levels in untreated and treated MS patients (anti-N negative) who received two doses of BNT162b2 vaccine

<table>
<thead>
<tr>
<th>Therapy</th>
<th>N.</th>
<th>Median anti-S in U/ml (IQR 25-75)</th>
<th>IRR</th>
<th>SE</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALEM</td>
<td>16</td>
<td>2310 (1132-3480)</td>
<td>1.385</td>
<td>0.266</td>
<td>0.222</td>
</tr>
<tr>
<td>IFN</td>
<td>131</td>
<td>1676 (904-3556)</td>
<td>1.258</td>
<td>0.123</td>
<td>0.063</td>
</tr>
<tr>
<td>GA</td>
<td>90</td>
<td>1524 (899-2954)</td>
<td>1.123</td>
<td>0.133</td>
<td>0.383</td>
</tr>
<tr>
<td>UNT</td>
<td>199</td>
<td>989 (538-1977)</td>
<td></td>
<td></td>
<td>reference</td>
</tr>
<tr>
<td>DMF</td>
<td>151</td>
<td>1250 (761-2108)</td>
<td>0.867</td>
<td>0.118</td>
<td>0.228</td>
</tr>
<tr>
<td>NAT</td>
<td>72</td>
<td>1268 (691-2359)</td>
<td>0.725</td>
<td>0.152</td>
<td>0.034</td>
</tr>
<tr>
<td>TER</td>
<td>55</td>
<td>619 (283-1273)</td>
<td>0.507</td>
<td>0.157</td>
<td>1.44E-05</td>
</tr>
<tr>
<td>AZA</td>
<td>27</td>
<td>342 (165-994)</td>
<td>0.374</td>
<td>0.212</td>
<td>3.26E-06</td>
</tr>
<tr>
<td>RTX</td>
<td>13</td>
<td>30.9 (8-52.7)</td>
<td>0.218</td>
<td>0.309</td>
<td>8.36E-07</td>
</tr>
<tr>
<td>FTY</td>
<td>71</td>
<td>26.7 (8-87.9)</td>
<td>0.133</td>
<td>0.154</td>
<td>1.89E-39</td>
</tr>
<tr>
<td>OCR</td>
<td>42</td>
<td>8 (8-89.7)</td>
<td>0.102</td>
<td>0.177</td>
<td>4.88E-38</td>
</tr>
</tbody>
</table>

Abbreviation: SE= Standard Error, IQR=interquantile range, IRR=Incidence Rate Ratio calculated as \( \exp(\text{coefficient}) \) (12)
**Figures**

**Figure 1**

(A) Antibody response to SARS-CoV-2 vaccination by DMT in MS patients (UNT=untreated; ALEM=alemtuzumab; IFN=interferon; GA=glatiramer acetate; DMF=dimethyl fumarate; NAT=natalizumab; CLA=cladribine; TER=teriflunomide; AZA=azathioprine; FTY=fingolimod; RTX=rituximab; OCR=ocrelizumab) and healthy control (HC) negative for anti-N antibodies.

(B) Antibody response to SARS-CoV-2 vaccination by DMT in MS patients positive for anti-N antibodies.

In A and B red dotted lines indicate a cutoff value of 133 U/ml predictive of the presence of neutralizing antibodies according to Resman et al (21). Results are reported as boxplots, showing the median value (in bold) and the quartiles as box limits; whiskers at the top and bottom sides represent the overall maximum value and the overall minimum value, respectively. Points outside boxes and whiskers represent outliers. (*P< 0.05; **P<0.001).
Figure 2

Impact of sex, age and smoking on humoral response to BNT162b2 vaccine.
Antibody response to SARS-CoV-2 vaccination by age (A), sex (B) and smoking status (C) in MS patients is represented. Results are reported as boxplots, showing the median value (in bold) and the quartiles as box limits; the whiskers at the top and bottom sides represent the overall maximum value and the overall minimum value, respectively. Data outside boxes and whiskers represent outliers. (**P<0.01; ***P<0.001).